ITM to Announce Dosimetry Data from the Phase 3 COMPETE Trial at SNMMI 2026 and Host Satellite Symposium
Garching / Munich, May 19, 2026 –– ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that dosimetry data from its Phase 3 COMPETE trial will be provided in a poster presentation at the Society of …